1. Report Industry Investment Rating - The industry rating is "Bullish" [1] 2. Core Views of the Report - The cosmetics industry continues to show differentiation, with brand demand being weak in the off - season, agents seeking change in difficult situations, and producers seizing supply - chain reconstruction opportunities. The medical aesthetics industry has new entrants with better - than - expected shipments, and new product catalysts are worth attention [3][4] 3. Summaries According to Relevant Catalogs 3.1 Cosmetics: Continued Differentiation 3.1.1 Brand Merchants - In 1 - 3Q25, beauty brand merchants' revenue was 28.4 billion yuan, a year - on - year decrease of 0.6%; personal care brand merchants' revenue was 5.7 billion yuan, a year - on - year increase of 12.4%. In 3Q25, beauty and personal care brand merchants' revenues were 8.05 billion and 1.805 billion yuan, a year - on - year decrease of 1.3% and an increase of 7.6% respectively. Beauty revenue weakened quarter - on - quarter, while personal care remained flat [18] - Beauty: Affected by the earlier Double Eleven promotion, consumer enthusiasm declined in September, and brands reduced live - streaming activities. In terms of single - quarter revenue growth, Shuiyang Co., Ltd. and Shanghai Jahwa increased by over 20%, Marubi Co., Ltd. had double - digit growth, Proya had low - double - digit decline, and Betaine and Freda had high - single - digit decline [18] - Personal care: Runben Co., Ltd.'s Q3 revenue increased by 17% year - on - year, with a slight increase in growth rate quarter - on - quarter. Baiya Co., Ltd.'s 3Q25 revenue improved, and Dengkang Oral Care had steady growth [18] - In 1 - 3Q25, beauty brand merchants' net profit after non - recurring items was 2.33 billion yuan, a year - on - year decrease of 15%; personal care brand merchants' was 604 million yuan, a year - on - year decrease of 3.4%. Some companies showed initial cost - control effects [24] 3.1.2 Agents - Agents are seeking change in difficult situations by exploring three paths: incubating self - owned brands (represented by Ruoyuchen), using AI to reduce costs and increase efficiency (represented by Yiwow), and expanding high - growth categories (such as Qingmu Technology expanding into trendy toy agency operations) [30] - Ruoyuchen's self - owned brands Feicui and Zhanjia continued to gain momentum. In Q3, self - owned brand revenue was 451 million yuan, a year - on - year increase of 344.5%, accounting for 55.1%. Zhanjia's Q3 revenue was 227 million yuan, a year - on - year increase of 119%, and 1 - 3Q revenue was 680 million yuan. Feicui's Q3 revenue was 203 million yuan, a quarter - on - quarter increase of over 98.8%, and 1 - 3Q revenue was 362 million yuan [30] 3.1.3 Producers - Demand continued to recover, and the revenue of the producer sector increased by 9%, 17%, and 30% year - on - year from Q1 to Q3, with the growth rate increasing quarter by quarter [33] - QingSong Co., Ltd. focused on optimizing customers and product structure, and its profit turned positive for four consecutive quarters from 2Q24 to 1Q25. Jieya Co., Ltd. had increasing orders from overseas big customers, and its Q3 performance growth accelerated. Jiaheng Home Co., Ltd. increased revenue but not profit, mainly due to the short - term impact of the Huzhou base's capacity ramp - up [33] 3.2 Medical Aesthetics: New Entrants with Better - than - Expected Shipments 3.2.1 Upstream Consumables - The growth rate of demand expansion slowed down, and supply - side competition intensified. In terms of the cumulative number of Class III medical device approvals, hyaluronic acid > regenerative (Sculptra/Poly - L - Lactic Acid) > botulinum toxin > recombinant collagen. Old products of hyaluronic acid and regenerative types faced growth pressure, and the growth rate of recombinant collagen Class III medical device products slowed down significantly quarter - on - quarter [38] - Hyaluronic acid: Aimeike's revenue growth rate from 24Q1 to 25Q3 was + 28.2%/+2.3%/+1.1%/ - 7%/ - 18%/ - 25%/ - 21% year - on - year, showing a quarterly decline since 24Q2 [38] - Collagen: Jinbo Biotech's revenue growth rate from 24Q1 to 25Q1 was + 76%/+100%/+92%/+73%/+63% year - on - year, and in 2Q25/3Q25, it was + 30%/+13% year - on - year. On October 23, the "Recombinant Type I α1 Subtype Collagen Freeze - Dried Fiber" Class III medical device certificate of Giant Biogene was approved by NMPA [38] - Leapmed Medical's medical aesthetics shipments were better than expected, with Q3 medical service and health management business revenue of 320 million yuan, a year - on - year increase of 28%, and the revenue of Sculptra and Hydrodermabrasion reaching 86.1367 million yuan [36] 3.2.2 Downstream - The new model of Xinoxygen Medical Clinics showed high - growth potential. The Q3 revenue guidance was 150 - 170 million yuan, a year - on - year increase of 231% - 275%, and a quarter - on - quarter increase of 4% - 18%. It plans to implement the "100 - City, 1000 - Store" plan in the long term [40] - Stores are expanding from first - tier cities to new first - tier and second - tier cities. As of November 6, it covered 42 stores in 10 cities. The promotion of self - owned brands was remarkable, and it cooperated with Xihong Miracle Sculptra 3.0, priced at 2999 yuan, which was officially launched on September 25 [43] 3.3 Investment Recommendations - Brands with upward potential and both growth and certainty: Recommend Maogeping (Oriental aesthetics, dual - wheel drive of makeup and skincare, and the second - curve of perfume is worth looking forward to) and Shangmei Co., Ltd. (with one cornerstone brand, five growth brands, and N seed businesses) [8][46] - Companies with new product pipelines and expected performance elasticity: Pay attention to Giant Biogene and Leapmed Medical [8][46] - Companies in strategic adjustment and expected to reach an inflection point: Recommend Shuiyang Co., Ltd. (the effect of high - end transformation is gradually emerging), and pay attention to Shanghai Jahwa, Betaine, and Freda [8][46]

Market Overview - The US stock market saw slight gains on Wednesday, with the S&P 500 index rising by 0.37% to 6796.29 points, the Nasdaq Composite increasing by 0.65% to 23499.8 points, and the Dow Jones Industrial Average up by 0.48% to 47311 points [1]. Economic Indicators - Following sharp questioning of Trump's tariffs by the US Supreme Court, traders reduced the probability of a government victory in the market [4]. - Ford and General Motors, as economic indicators, both rose over 2%, while Caterpillar saw an increase of nearly 4% [4]. Technology Sector - AI concept stocks experienced a turnaround, with AMD rebounding after an initial drop, and companies like Broadcom, Google, and Oracle also seeing gains [5]. - Micron Technology surged by 8.93%, reaching a historical high, driven by rumors of rising HBM4 chip prices. Other storage stocks like Seagate and SanDisk also rose over 10% [6]. - However, not all AI stocks rebounded; AMD's competitor, Supermicro, fell over 11%, and Arista Networks dropped nearly 9% [7]. Stock Performance - Notable stock performances included Nvidia down 1.75%, Apple up 0.04%, Microsoft down 1.39%, Google-C up 2.41% (hitting a historical closing high), Amazon up 0.35%, and Tesla up 4.01% [8]. Renewable Energy Sector - Solid Power's stock surged by 51.56% after a favorable earnings report, while SolarEdge rose by 28.91%, boosting the battery storage and solar panel sectors overall [9]. Chinese Stocks - The Nasdaq Golden Dragon China Index saw a slight increase of 0.15%. Key performances included Alibaba up 0.32%, JD.com up 0.69%, and Pinduoduo up 1.87%, while NIO fell by 3.97% [10].

Core Viewpoint - The stock price of New Oxygen (SY.US) increased by over 14%, reaching $4.04, following the announcement of its upcoming financial results for Q3 2025, which will be released before the market opens on November 17, 2025 [1] Group 1 - New Oxygen's stock price rose significantly, indicating positive market sentiment [1] - The company is scheduled to announce its Q3 financial results for the period ending September 30, 2025 [1]

Core Viewpoint - The stock price of New Oxygen (SY.US) increased by over 14%, reaching $4.04, following the announcement of its upcoming financial results for Q3 2025 [1] Financial Performance - New Oxygen is set to release its financial results for the third quarter ending September 30, 2025, on November 17, 2025, before the U.S. market opens [1]

Core Viewpoint - So-Young International Inc. is set to report its financial results for the third quarter of 2025 on November 17, 2025, before U.S. markets open [1]. Company Overview - So-Young International Inc. is the leading aesthetic treatment platform in China, connecting consumers with online services and offline treatments [3]. - The company provides access to aesthetic treatments through its online platform and branded aesthetic centers, offering curated treatment information, facilitating online reservations, and delivering high-quality treatments [3]. - So-Young also develops, produces, and distributes optoelectronic medical equipment and injectable products, positioning itself well for long-term growth in the medical aesthetic value chain [3]. Earnings Conference Call - The management will hold an earnings conference call on November 17, 2025, at 7:00 AM U.S. Eastern Time [2]. - Dial-in details for the conference call include international and local numbers for various regions, with a passcode provided for access [2]. - A telephone replay will be available two hours after the call, and a live and archived webcast will be accessible on the company's investor relations website [2].

Core Viewpoint - Chinese concept stocks experienced significant gains, with Kuke Music leading the surge with a remarkable increase of 321.3% in its stock price [1]. Group 1: Stock Performance - Kuke Music (KUKEY) saw a price increase to 0.4213, up 321.3%, with a gain of 0.3213 and a trading volume of 1.22 billion [1]. - EZGO (EZGO) rose by 29.11% to 0.1752, gaining 0.0395, with a trading volume of 46.41 million [1]. - Gran Capital (GRAN) increased by 23.9% to 3.085, with a gain of 0.595 and a trading volume of 112,400 [1]. - Agencia Comercial Sp (AGCC) experienced a 19.81% rise to 6.410, gaining 1.060, with a trading volume of 1.25 million [1]. - New Oxygen (SY) rose by 19.24% to 3.470, with a gain of 0.560 and a trading volume of 9.95 million [1].

Core Points - The market shows signs of concern despite a strong start to November, traditionally known as a strong month for US stocks, with the S&P 500 index rising by 0.17% and the Nasdaq Composite by 0.46%, while the Dow Jones Industrial Average fell by 0.48% [1] - Amazon AWS announced a $38 billion computing power contract with OpenAI, marking a significant partnership within the "Big Seven" tech companies [2] - Microsoft signed a $9.7 billion computing power contract with Australian cloud service provider IREN, and Lambda also secured a multi-billion dollar contract with Microsoft [5] - Nvidia's stock rose over 2%, contributing to a market capitalization increase of over $100 billion, driven by news of chip exports to the UAE [5] - Google issued $17.5 billion in bonds in the US market, following a €6.5 billion issuance in Europe, receiving approximately $90 billion in orders [5] - Despite the S&P 500 index reaching new highs, over 400 stocks in the index declined during the trading session, indicating a divergence between index performance and market breadth [5] - Historical data shows November has been the best-performing month for US stocks over the past 30 years, with an average gain of 2.6% when the S&P 500 is up over 10% year-to-date [6][7] Company Performance - Amazon's market capitalization increased by $104.5 billion, equivalent to approximately ¥743.7 billion, following the announcement of its contract with OpenAI [2] - Nvidia's stock rose by 2.17%, while other major tech stocks like Apple and Microsoft saw slight declines [8] - Tesla's stock increased by 2.59%, while other companies like Meta and Berkshire Hathaway experienced declines [8] - Chinese concept stocks showed mixed performance, with the Nasdaq Golden Dragon China Index rising by 0.26% [9] Other Industry News - The US electric vehicle market faced a significant drop in sales due to the expiration of federal purchase subsidies, with Hyundai reporting an 80% drop in sales for its Ioniq 5 and 71% for the Ioniq 9 [10] - Kimberly-Clark's stock fell by 14.57% after announcing a $48.7 billion acquisition of Kenvue, while Kenvue's stock rose by 12.32% [11] - Tesla's sales in Europe continued to decline, with a reported 89% drop in Sweden and 86% in Denmark, although there was slight growth in France [12] - Berkshire Hathaway's third-quarter report indicated a $1.2 billion decrease in the value of its Apple holdings, suggesting potential further reductions in its stake [13]

Group 1: Amazon - Amazon's stock price surged by 12.2% at opening, with market capitalization increasing by $274.2 billion (approximately ¥1.95 trillion) [2] - In Q3, Amazon reported net sales of $180.2 billion, a 13% year-over-year increase, surpassing market expectations of $177.8 billion; net profit reached $21.2 billion, up nearly 40% [4] - AWS cloud business revenue grew by 20% year-over-year to $33 billion, exceeding analyst expectations and marking the strongest growth since 2022, alleviating concerns about AWS lagging in the AI competition [4] Group 2: Apple - Apple reached a historical high in stock price before a short-term decline; Q4 revenue was $102.47 billion, exceeding $100 billion and marking a year-over-year increase of 8% [5] - Net profit for Q4 was $27.47 billion, a significant year-over-year increase of 86%, with diluted earnings per share rising by 91% to $1.85 [5] - Despite overall strong performance, revenue from Greater China declined by 3.6%, becoming the only region with negative growth [5] Group 3: Cryptocurrency - Most cryptocurrencies saw an increase, with Bitcoin returning to the $110,000 mark, up 2.81%, Ethereum at $3,874, up 2.39%, and Dogecoin rising over 3% [7] Group 4: Gold Market - The World Gold Council noted that geopolitical tensions, persistent inflation, and uncertainty in global trade policies have driven demand for gold as a safe-haven asset [6] - The outlook for the gold market remains optimistic, supported by a weakening dollar, expectations of rate cuts, and the risk of stagflation, indicating further potential for gold price increases [6]

Investment Focus - Amazon is the largest player in the cloud industry with a global market share of 30%, benefiting from scale effects that stabilize and improve margins [1] - Google is expected to see improvements in margins due to rising IaaS cloud scale, with a projected margin increase of over 20% by year-end [1] - Alibaba's cloud revenue reached 33.4 billion RMB in Q1 FY26, demonstrating strong growth driven by instant retail and cloud business resilience [1] Hardware & AI - Arista Networks is a leader in high-end data center network switches, with expected revenue contribution of at least $750 million from AI backend switches in 2025 [3] - NVIDIA's data center business, which accounts for 88% of its revenue, is projected to see strong growth driven by AI capital expenditures, with a target price of $204.35 based on a 30x FY2027 EPS [4] - SK Hynix is expected to benefit from recovering downstream inventory and a doubling of HBM sales this year, with a target price of KRW 280,555 [3] Internet & Services - Tencent Music is expected to see steady revenue growth driven by its core subscription business and new high-margin services, with a focus on expanding its content offerings [4] - Futu Holdings is projected to maintain strong growth in paid user numbers and AUM, benefiting from its virtual asset business and competitive valuation [6] - JoYY's core overseas live streaming business is stabilizing, supported by a favorable policy environment and strong industry demand [5] Pharmaceuticals - Hansoh Pharmaceutical is expected to see innovative drug revenue exceed 10 billion in 2025, with a significant contribution from milestone payments [8] - Innovent Biologics is focusing on expanding its ADC platforms, with potential peak sales of its pipeline products reaching 100 billion [8] - Kintor Pharmaceutical's innovative pipeline is expected to drive significant revenue growth, with a strong cash reserve of over $2 billion [9]

Core Viewpoint - The introduction of a low-priced "童颜针" (youthful needle) by the medical beauty platform 新氧 (SoYoung) at a price of 2999 yuan has sparked significant discussion in the medical beauty industry, challenging the long-standing high price barrier while raising concerns about quality and industry dynamics [1][5][12]. Pricing Strategy - 新氧's new product is priced at 2999 yuan, significantly lower than the average market price of 12800 yuan in China and even lower than prices in neighboring countries [1][3]. - The company aims to disrupt the high-price market by leveraging scale effects and a low-margin strategy, eliminating middlemen and directly collaborating with upstream manufacturers [4][11]. - The cost structure of traditional high-priced "童颜针" indicates that raw material costs account for only 10%-20%, while marketing and channel expenses can take up 30%-40% [3][4]. Market Dynamics - The market for "童颜针" is rapidly growing, with projections estimating the B-end market size to reach 4.2 billion yuan by 2025, up from 500 million yuan in 2021 [1][12]. - The introduction of low-priced options may lead to increased competition, with the potential for a price war among smaller clinics, while larger institutions may benefit from their scale and operational capabilities [10][12]. Quality Concerns - The low pricing strategy has raised questions about the reliability and quality of the product, especially given the quality control issues faced by the manufacturing partner, 西宏生物 (Xihong Bio) [8][12]. - Concerns have been voiced that some medical institutions may cut costs in operational processes to maintain profitability, potentially compromising quality [8][10]. Industry Transformation - 新氧's pricing strategy is seen as a potential disruptor in the medical beauty industry, which is currently experiencing a cycle of high costs leading to high prices, driving consumers towards unregulated options [12][13]. - The company's offline business is emerging as a new growth point, with a significant increase in revenue from its chain clinics, which have grown to 40 locations and are expected to reach 50 by year-end [15]. - Despite the aggressive transformation, 新氧 has faced challenges, with overall revenue declining by 7% year-on-year to 379 million yuan, and a net loss of 36 million yuan reported [15].